TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities
